Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New JAK1 inhibitors identified at HK inno.N Corp.

June 5, 2020

Onconova Therapeutics describes multi-specific protein kinase inhibitors

June 5, 2020

EZH2 has dual role

June 5, 2020

Phase II dose defined in trial of CBL-0137 in patients with solid tumors

June 4, 2020

European approval for Braftovi with cetuximab for BRAF V600E-mutant metastatic colorectal cancer

June 4, 2020

New MAP4K1 inhibitors discovered at Pfizer

June 4, 2020

Shanghai Ennova Biopharmaceutical patents neurotrophic tyrosine kinase receptor inhibitors

June 4, 2020

Ube Industries discloses cyclin-dependent kinase 7 inhibitors

June 4, 2020

Phase II data reported from TreeTopp study of varlitinib plus capecitabine in BTC

June 4, 2020

Rgenix presents monotherapy dose-escalation data from phase I study of RGX-202

June 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...